Suppr超能文献

相似文献

2
X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB).
J Mol Biol. 2007 Feb 16;366(2):469-80. doi: 10.1016/j.jmb.2006.11.006. Epub 2006 Nov 7.
4
Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin.
J Biol Chem. 2010 Feb 26;285(9):6161-9. doi: 10.1074/jbc.M109.077909. Epub 2009 Dec 16.
8
Effect of thiolactomycin on the individual enzymes of the fatty acid synthase system in Escherichia coli.
J Biochem. 1986 May;99(5):1447-54. doi: 10.1093/oxfordjournals.jbchem.a135614.
9
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
J Med Chem. 2016 Jun 9;59(11):5377-90. doi: 10.1021/acs.jmedchem.6b00236. Epub 2016 May 24.
10
Synthesis and biological evaluation of thiazolidine-2-one 1,1-dioxide as inhibitors of Escherichia coli beta-ketoacyl-ACP-synthase III (FabH).
Bioorg Med Chem Lett. 2007 Feb 15;17(4):879-83. doi: 10.1016/j.bmcl.2006.11.067. Epub 2006 Dec 1.

引用本文的文献

1
: Pathogenesis and therapeutic targets.
MedComm (2020). 2023 Sep 4;4(5):e353. doi: 10.1002/mco2.353. eCollection 2023 Oct.
2
KasA as a drug target: Structure-based inhibitor design.
Front Cell Infect Microbiol. 2022 Sep 15;12:1008213. doi: 10.3389/fcimb.2022.1008213. eCollection 2022.
3
A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.
Cell Chem Biol. 2020 May 21;27(5):560-570.e10. doi: 10.1016/j.chembiol.2020.02.007. Epub 2020 Mar 19.
4
Synthesis, bioactivity, and enzymatic modification of antibacterial thiotetromycin derivatives.
Org Biomol Chem. 2019 Mar 27;17(13):3416-3423. doi: 10.1039/c8ob03109f.
5
Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target.
Parasitology. 2018 Feb;145(2):116-133. doi: 10.1017/S0031182016002377. Epub 2016 Dec 15.
6
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
J Med Chem. 2016 Jun 9;59(11):5377-90. doi: 10.1021/acs.jmedchem.6b00236. Epub 2016 May 24.
8
Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening.
Bioorg Med Chem Lett. 2014 Jun 1;24(11):2585-8. doi: 10.1016/j.bmcl.2014.03.033. Epub 2014 Apr 2.
9
Chemotherapeutic interventions against tuberculosis.
Pharmaceuticals (Basel). 2012 Jun 28;5(7):690-718. doi: 10.3390/ph5070690.
10
New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.
Curr Pharm Des. 2014;20(27):4357-78. doi: 10.2174/1381612819666131118203641.

本文引用的文献

3
Prospects for new antitubercular drugs.
Curr Opin Microbiol. 2004 Oct;7(5):460-5. doi: 10.1016/j.mib.2004.08.011.
4
Refinement of macromolecular structures by the maximum-likelihood method.
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55. doi: 10.1107/S0907444996012255.
5
Short synthesis of the 6,6-spiroketal cores of spirofungins A and B.
Org Lett. 2004 Jul 22;6(15):2587-90. doi: 10.1021/ol0491078.
6
Fatty acid biosynthesis as a target for novel antibacterials.
Curr Opin Investig Drugs. 2004 Feb;5(2):146-53.
7
Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents.
Bioorg Med Chem. 2004 Feb 15;12(4):683-92. doi: 10.1016/j.bmc.2003.11.023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验